Literature DB >> 27109821

Characterisation of fatigue and its substantial impact on health status in a large cohort of patients with chronic pulmonary aspergillosis (CPA).

Khaled Al-Shair1, Eavan G Muldoon1, Julie Morris2, Graham T Atherton1, Chris Kosmidis1, David W Denning3.   

Abstract

INTRODUCTION: Fatigue is a prominent disabling symptom in several pulmonary diseases. Its impact on health status in patients with chronic pulmonary aspergillosis (CPA) has not been investigated.
METHODS: A total of 151 CPA patients attending the National Aspergillosis Centre completed Manchester COPD Fatigue Scale (MCFS), St. George's Respiratory Questionnaire (SGRQ) and Medical Research Council (MRC) dyspnoea score. Lung function and BMI were measured. Univariate, multivariate linear and binary analyses, and principal component analysis (PCA) were used.
RESULTS: Female patients accounted for 44%. The mean (range) of age was 59.6 (31-83) years, FEV1% was 64 (14-140), BMI was 23.6 (16.3-43.4), SGRQ total score was 56 (4-96.2) and MCFS total score was 30.6 (0-54). PCA showed that 27 items of MCFS loaded on three components; physical, psychosocial and cognitive fatigue, explaining 78.4% of fatigue variance. MCFS score correlated strongly with total SGRQ score (r = 0.83, p < 0.001). Using linear multivariate analysis, fatigue was the strongest factor (beta = 0.7 p < 0.0001) associated with impaired health status, after adjusting for age, BMI, FEV1%, and MRC dyspnoea score. Using patients' 5 self-assessment grades of their health, one-way ANOVA showed that those with "very poor" health status had the highest fatigue scores (45 (±6) (p < 0.001)). Logistic regression analysis showed that fatigue score (OR = 0.9, 95% CI 0.84-0.97; p = 0.005) and FEV1% (OR = 1.03, 95% CI 1.01-1.07, p = 0.02) are significantly associated with self-assessed impaired health status after correcting for age, gender and DLCO%.
CONCLUSION: Fatigue is a major component of impaired health status of CPA patients.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aspergilloma; Chronic pulmonary aspergillosis; Fatigue; Health status

Mesh:

Year:  2016        PMID: 27109821     DOI: 10.1016/j.rmed.2016.03.020

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  6 in total

1.  Chronic pulmonary aspergillosis in patients with active pulmonary tuberculosis with persisting symptoms in Uganda.

Authors:  Martha Namusobya; Felix Bongomin; John Mukisa; William Kane Olwit; Charles Batte; Claudine Mukashyaka; Emmanuel Mande; Richard Kwizera; David W Denning; Joshua Rhein; Shailendra Prasad; Christine Sekaggya-Wiltshire
Journal:  Mycoses       Date:  2022-04-24       Impact factor: 4.931

2.  Incidence and Risk Factors of Chronic Pulmonary Aspergillosis Development during Long-Term Follow-Up after Lung Cancer Surgery.

Authors:  Sun Hye Shin; Bo-Guen Kim; Jiyeon Kang; Sang-Won Um; Hojoong Kim; Hong Kwan Kim; Jhingook Kim; Young Mog Shim; Yong Soo Choi; Byeong-Ho Jeong
Journal:  J Fungi (Basel)       Date:  2020-11-09

3.  A prospective longitudinal study of chronic pulmonary aspergillosis in pulmonary tuberculosis in Indonesia (APICAL).

Authors:  Findra Setianingrum; Anna Rozaliyani; Robiatul Adawiyah; Ridhawati Syam; Mulyati Tugiran; Cut Yulia Indah Sari; Finny Nandipinto; Johannes Ramnath; Arief Riadi Arifin; Diah Handayani; Erlina Burhan; Martin Rumende; Retno Wahyuningsih; Riina Rautemaa-Richardson; David W Denning
Journal:  Thorax       Date:  2021-11-30       Impact factor: 9.102

4.  The Effect of Fatigue and Fatigue Intensity on Exercise Tolerance in Moderate COPD.

Authors:  Khaled Al-Shair; Umme Kolsum; Dave Singh; Jørgen Vestbo
Journal:  Lung       Date:  2016-08-22       Impact factor: 2.584

Review 5.  The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach.

Authors:  Firas Maghrabi; David W Denning
Journal:  Curr Fungal Infect Rep       Date:  2017-11-13

Review 6.  Fatigue in Chronic Respiratory Diseases: Theoretical Framework and Implications For Real-Life Performance and Rehabilitation.

Authors:  Mathieu Gruet
Journal:  Front Physiol       Date:  2018-09-19       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.